PIRS News and Press, Pieris Pharmaceuticals Inc. From 05/10/23

2023-05-10 11:03:07 ET Pieris Pharmaceuticals, Inc. (PIRS) Q1 2023 Earnings Conference Call May 10, 2023, 08:00 AM ET Company Participants Thomas Bures - CFO Stephen Yoder - President and CEO Shane Olwill - Chief Development Officer Conference Call Particip...

2023-05-10 07:11:28 ET Pieris Pharmaceuticals press release ( NASDAQ: PIRS ): Q1 GAAP EPS of -$0.18 misses by $0.04 . Revenue of $1.94M (-82.3% Y/Y) misses by $4.57M . For further details see: Pieris Pharmaceuticals GAAP EPS of -$0.18 misses by $0.04, rev...

COMPANY TO HOST AN INVESTOR CONFERENCE CALL TODAY, WEDNESDAY, MAY 10, 2023, AT 8:00 AM EDT Enrollment for elarekibep (PRS-060/AZD1402) Phase 2a study for asthma continues to progress with topline clinical data anticipated by mid-2024; successful safety review completed for 10 mg dose cohort...

2023-05-09 11:38:25 ET Pieris Pharmaceuticals ( NASDAQ: PIRS ) is scheduled to announce Q1 earnings results on Wednesday, May 10th, before market open. The consensus EPS Estimate is -$0.09 (-28.6% Y/Y) and the consensus Revenue Estimate is $6.51M (-40.8% Y/Y). Over the...

BOSTON, MA / ACCESSWIRE / May 4, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform for respiratory diseases, cancer, and other indications, today announced the ...

BOSTON, MA / ACCESSWIRE / May 2, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform for respiratory diseases, cancer and other indications, today announced tha...

2023-04-17 14:33:27 ET Pieris Pharmaceuticals ( NASDAQ: PIRS ) added ~11% on Monday after announcing the latest data for its investigational bispecific cinrebafusp alfa from a mid-stage trial for patients with HER2-positive gastric cancer at the ongoing annual meeting of the A...

BOSTON, MA / ACCESSWIRE / April 17, 2023 / Pieris Pharmaceuticals, Inc. (Nasdaq:PIRS ), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, announced the...

2023-03-29 15:41:29 ET The following slide deck was published by Pieris Pharmaceuticals, Inc. in conjunction with their 2022 Q4 earnings call. For further details see: Pieris Pharmaceuticals, Inc. 2022 Q4 - Results - Earnings Call Presentation

2023-03-29 15:40:06 ET Pieris Pharmaceuticals, Inc. (PIRS) Q4 2022 Results Earnings Conference Call March 29, 2023, 08:00 AM ET Company Participants Thomas Bures - Senior Vice President and Chief Financial Officer Stephen Yoder - President and Chief Executive Officer...